| Good research practices for cost‐effectiveness analysis alongside clinical trials: the ISPOR RCT‐CEA Task Force report S Ramsey, R Willke, A Briggs, R Brown, M Buxton, A Chawla, J Cook, ... Value in health 8 (5), 521-533, 2005 | 789 | 2005 |
| Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good Research Practices Task Force report SD Ramsey, RJ Willke, H Glick, SD Reed, F Augustovski, B Jonsson, ... Value in health 18 (2), 161-172, 2015 | 734 | 2015 |
| Good practices for real‐world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in … ML Berger, H Sox, RJ Willke, DL Brixner, HG Eichler, W Goettsch, ... Value in Health 20 (8), 1003-1008, 2017 | 553 | 2017 |
| Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels RJ Willke, LB Burke, P Erickson Controlled clinical trials 25 (6), 535-552, 2004 | 408 | 2004 |
| Confidence intervals for cost–effectiveness ratios: a comparison of four methods D Polsky, HA Glick, R Willke, K Schulman Health economics 6 (3), 243-252, 1997 | 353 | 1997 |
| Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or … Z Li, RJ Willke, LA Pinto, BE Rittenhouse, MJ Rybak, AM Pleil, CW Crouch, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (3 …, 2001 | 199 | 2001 |
| Association between vision loss and higher medical care costs in Medicare beneficiaries: costs are greater for those with progressive vision loss JC Javitt, Z Zhou, RJ Willke Ophthalmology 114 (2), 238-245. e1, 2007 | 190 | 2007 |
| An overview of value, perspective, and decision context—a health economics approach: an ISPOR Special Task Force report [2] LP Garrison Jr, MV Pauly, RJ Willke, PJ Neumann Value in health 21 (2), 124-130, 2018 | 187 | 2018 |
| Estimating country‐specific cost‐effectiveness from multinational clinical trials RJ Willke, HA Glick, D Polsky, K Schulman Health economics 7 (6), 481-493, 1998 | 160 | 1998 |
| A health economics approach to US value assessment frameworks—introduction: an ISPOR Special Task Force report [1] PJ Neumann, RJ Willke, LP Garrison Jr Value in Health 21 (2), 119-123, 2018 | 159 | 2018 |
| Variability of cost‐effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability M Barbieri, M Drummond, R Willke, J Chancellor, B Jolain, A Towse Value in health 8 (1), 10-23, 2005 | 156 | 2005 |
| A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR special task force report [7] LP Garrison Jr, PJ Neumann, RJ Willke, A Basu, PM Danzon, JA Doshi, ... Value in Health 21 (2), 161-165, 2018 | 155 | 2018 |
| Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients KP Weinfurt, RJ Willke, HA Glick, WW Freimuth, KA Schulman Medical care 38 (4), 404-410, 2000 | 140 | 2000 |
| Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease IC Huang, C Frangakis, MJ Atkinson, RJ Willke, WL Leite, WB Vogel, ... Health services research 43 (1p1), 327-339, 2008 | 126 | 2008 |
| Resource costing for multinational neurologic clinical trials: methods and results K Schulman, J Burke, M Drummond, L Davies, P Carlsson, J Gruger, ... Health Economics 7 (7), 629-638, 1998 | 121 | 1998 |
| Incidence of exudative age-related macular degeneration among elderly Americans JC Javitt, Z Zhou, MG Maguire, SL Fine, RJ Willke Ophthalmology 110 (8), 1534-1539, 2003 | 114 | 2003 |
| Improving transparency to build trust in real-world secondary data studies for hypothesis testing—why, what, and how: recommendations and a road map from the real-world … LS Orsini, M Berger, W Crown, G Daniel, HG Eichler, W Goettsch, J Graff, ... Value in Health 23 (9), 1128-1136, 2020 | 112 | 2020 |
| Reverse engineering and evaluation of prediction models for progression to type 2 diabetes: an application of machine learning using electronic health records JP Anderson, JR Parikh, DK Shenfeld, V Ivanov, C Marks, BW Church, ... Journal of diabetes science and technology 10 (1), 6-18, 2016 | 112 | 2016 |
| Quality of life effects of alprostadil therapy for erectile dysfunction RJ Willke, HA Glick, TJ McCarron, MH Erder, SE Althof, OI Linet The Journal of urology 157 (6), 2124-2128, 1997 | 107 | 1997 |
| Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant … JZ Li, RJ Willke, BE Rittenhouse, MJ Rybak Surgical Infections 4 (1), 57-70, 2003 | 106 | 2003 |
Brian RittenhouseProfessor MCPHS在 mcphs.edu 的电子邮件经过验证
